A team of researchers at Boston Children's Hospital has developed an innovative way to knock out the oncogene Lipocalin 2 using the editing system CRISPR and has shown its potential for treating triple-negative breast tumors in mice.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,